Peptide and Oligonucleotide CDMO Market: Global Industry Analysis and Forecast (2023 – 2029)

The Global Peptide and Oligonucleotide CDMO Market size was valued at USD 1.7 billion in 2022. The report projects that the market will grow at a compound annual growth rate (CAGR) of 10.7% from 2023 to 2029.

Peptide and Oligonucleotide CDMO Market Overview:

The global Peptide and Oligonucleotide CDMO (Contract Development and Manufacturing Organization) market is experiencing substantial growth due to several key factors. This includes the increasing demand for peptide and oligonucleotide-based therapeutics, advancements in peptide synthesis and oligonucleotide manufacturing technologies, and the outsourcing trend in the pharmaceutical industry. Peptides are short chains of amino acids that play crucial roles in various biological processes and have gained significant attention as potential therapeutics for a wide range of diseases. Oligonucleotides, on the other hand, are short nucleic acid sequences that can modulate gene expression and are being explored for their therapeutic applications, particularly in areas such as gene therapy, oncology, and rare genetic disorders. The Peptide and Oligonucleotide CDMO market is segmented based on services, including peptide synthesis, oligonucleotide synthesis, analytical services, formulation development, and other related services. CDMOs offer expertise in peptide and oligonucleotide synthesis, process development, scale-up, and manufacturing, providing pharmaceutical and biotechnology companies with the necessary capabilities and infrastructure to bring these complex therapeutics to market. Key players in the Peptide and Oligonucleotide CDMO market include companies such as Lonza Group AG, Bachem Holding AG, CordenPharma International, PolyPeptide Group, and GenScript Biotech Corporation. These companies offer a wide range of services, including custom peptide synthesis, large-scale peptide manufacturing, oligonucleotide synthesis, and formulation development, catering to the diverse needs of pharmaceutical and biotechnology clients.Peptide and Oligonucleotide CDMO MarketTo know about the Research Methodology :- Request Free Sample Report

Peptide and Oligonucleotide CDMO Market Research Methodology:

The research methodology for the Peptide and Oligonucleotide CDMO (Contract Development and Manufacturing Organization) Market involves a combination of quantitative and qualitative elements. The market is extensively researched using primary and secondary data sources, with a focus on understanding market trends, customer preferences, and industry challenges specific to peptide and oligonucleotide CDMO. Primary research for the Peptide and Oligonucleotide CDMO Market involves collecting data through surveys, interviews, and focus groups with key stakeholders such as industry experts, CDMO providers, pharmaceutical companies, and end-users. These primary research methods help gather insights on market dynamics, customer needs, industry challenges, and emerging trends in peptide and oligonucleotide manufacturing. Secondary research for the Peptide and Oligonucleotide CDMO Market involves gathering data from published industry reports, company websites, annual reports, trade journals, scientific papers, and databases related to peptide and oligonucleotide manufacturing. To estimate the Peptide and Oligonucleotide CDMO Market size, growth potential, and forecast, a bottom-up approach is used. The market size for top-level markets and sub-segments is normalized, taking into account various factors such as economic conditions, regulatory changes, and market dynamics. The percentage splits, market shares, and breakdowns of the peptide and oligonucleotide CDMO market segments are derived based on weights assigned to each segment, considering factors such as their utilization rate and average contract value. The data is then analysed and synthesized to provide a comprehensive view of the market structure and segment-wise distribution. Country-wise analysis of the overall market and its sub-segments is conducted based on the percentage adoption or utilization of peptide and oligonucleotide CDMO services in each region or country. The report includes a comprehensive competitive analysis of key players in the Peptide and Oligonucleotide CDMO Market. Major players are identified through secondary research based on indicators such as market revenue, pricing, services offered, technological advancements, mergers and acquisitions, and partnerships. The analysis helps in understanding the drivers, restraints, opportunities, and challenges influencing the market growth. It also provides insights into the future prospects and potential risks associated with the peptide and oligonucleotide CDMO market.

Peptide and Oligonucleotide CDMO Market Scope:

The report provides a comprehensive analysis of the global Peptide and Oligonucleotide Contract Development and Manufacturing Organization (CDMO) market, covering the current market size, future growth prospects, key drivers, restraints, and opportunities influencing the market. It offers an in-depth analysis of the competitive landscape, market trends, and product innovations within the Peptide and Oligonucleotide CDMO market. The scope of the report includes a detailed segmentation analysis of the market based on service type, product type, end-user, and region. The market can be divided into two primary service types: Contract Development Services: This segment encompasses critical services such as process development, analytical method development, formulation development, and preclinical development. These contract development services play a crucial role in optimizing manufacturing processes, ensuring the quality and safety of peptides and oligonucleotides. Contract Manufacturing Services: This segment focuses on the manufacturing of peptides and oligonucleotides on a contract basis. It includes services such as small-scale and large-scale manufacturing, fill-finish operations, packaging, and labelling. Within the market, there are two key product types: Peptides: Peptides are short chains of amino acids linked together. They find diverse applications in therapeutics, diagnostics, and research. The market for peptide CDMO services involves the development and manufacturing of custom peptides, therapeutic peptides, and peptide-based products. Oligonucleotides: Oligonucleotides are short sequences of nucleotides. They are utilized in various applications, including gene synthesis, gene editing, molecular diagnostics, and therapeutics. The market for oligonucleotide CDMO services encompasses the development and manufacturing of custom oligonucleotides, antisense oligonucleotides, siRNA, miRNA, and other nucleic acid-based products. The report provides market size and forecast data for each of these segments, along with a market share analysis of key players in each segment. It also includes regional analysis, covering market trends, challenges, and opportunities that are likely to shape market growth in the forecast years. The growing pipeline of peptide and oligonucleotide-based therapeutics and diagnostics contributes to market growth. However, challenges associated with complex synthesis processes, quality control, and regulatory compliance may hinder market growth. The report aims to assist stakeholders, including pharmaceutical and biotechnology companies, research institutes, academic organizations, and investors, in making informed decisions and formulating effective strategies to capitalize on the opportunities in the Peptide and Oligonucleotide CDMO market and expand their business.

Peptide and Oligonucleotide CDMO Market Dynamics:

The Peptide and Oligonucleotide CDMO market is influenced by various drivers, restraints, opportunities, and trends. Understanding these dynamics is crucial for stakeholders in making informed decisions and capitalizing on market growth potential. Peptide and Oligonucleotide CDMO Market Drivers: Growing Demand for Peptide and Oligonucleotide Therapeutics: Peptides and oligonucleotides have gained attention as promising therapeutic modalities for various diseases, including cancer, metabolic disorders, and genetic diseases. The increasing prevalence of these conditions has driven the demand for peptide and oligonucleotide CDMOs. Advancements in Drug Delivery Technologies: Innovations in drug delivery systems, such as targeted delivery and sustained release formulations, have expanded the applications of peptides and oligonucleotides. CDMOs play a crucial role in developing and manufacturing these advanced drug delivery technologies, driving market growth. Rising R&D Investments: Pharmaceutical and biotechnology companies are investing heavily in research and development of peptide and oligonucleotide therapeutics. Outsourcing the development and manufacturing processes to CDMOs allows these companies to focus on core competencies while reducing costs and accelerating product development.

Peptide and Oligonucleotide CDMO Market Opportunities:

Personalized Medicine: Peptides and oligonucleotides have shown potential in personalized medicine approaches due to their ability to target specific disease markers or genetic mutations. The increasing demand for personalized therapies presents opportunities for CDMOs to develop customized peptide and oligonucleotide therapeutics. Emerging Markets: The demand for peptide and oligonucleotide therapeutics is expanding beyond developed regions, with emerging markets showing significant growth potential. CDMOs can tap into these markets by establishing strategic partnerships and expanding their manufacturing capabilities to meet the increasing demand.

Peptide and Oligonucleotide CDMO Market Trends:

Integrated Services: CDMOs are increasingly offering integrated services that encompass the entire drug development and manufacturing process, from early-stage development to commercial production. This trend allows for streamlined operations, cost efficiencies, and faster time to market. Process Automation and Digitization: Automation and digitization of manufacturing processes are becoming increasingly prevalent in the peptide and oligonucleotide CDMO sector. Robotic systems, artificial intelligence, and data analytics are being employed to enhance efficiency, accuracy, and quality control. Peptide and Oligonucleotide CDMO Market Restraints: Regulatory Challenges: Peptide and oligonucleotide therapeutics face regulatory challenges due to their complex structures and modes of action. CDMOs need to comply with stringent regulatory requirements, which can increase development and manufacturing timelines and costs. Manufacturing Capacity Constraints: The increasing demand for peptide and oligonucleotide therapeutics has put pressure on CDMOs to expand their manufacturing capacities. Building and validating new facilities can be time-consuming and capital-intensive, leading to capacity constraints in the short term. Intellectual Property Concerns: Peptides and oligonucleotides are subject to intellectual property rights, and CDMOs must navigate patent landscapes and protect their clients' proprietary information. Intellectual property concerns can pose challenges to innovation and market entry.

Peptide and Oligonucleotide CDMO Market segmentation:

by Product: Peptide CDMO:Solid Phase Peptide Synthesis (SPPS): Includes the production of peptides using solid-phase synthesis techniques. Liquid Phase Peptide Synthesis (LPPS): Involves the synthesis of peptides in solution phase. Hybrid Methods: Combines aspects of both SPPS and LPPS to optimize peptide synthesis efficiency. Reagents and Consumables: Encompasses the various chemicals, resins, and other materials utilized in peptide synthesis processes. DNA Oligonucleotides: Involves the synthesis of short DNA sequences used in various applications such as gene editing, PCR, and DNA sequencing. RNA Oligonucleotides: Includes the synthesis of RNA sequences used in applications such as mRNA therapeutics, RNA interference (RNAi), and antisense oligonucleotides. by Application: Peptide Therapeutics: Includes the development of peptide-based drugs for various therapeutic areas, such as oncology, metabolic disorders, and cardiovascular diseases. Oligonucleotide Therapeutics: Involves the production of oligonucleotide-based drugs, including antisense oligonucleotides, siRNA, and mRNA therapeutics. Research and Diagnostics: Peptide Libraries: Involves the production of diverse peptide libraries used in high-throughput screening for drug discovery and target identification. Oligonucleotide Probes: Includes the synthesis of labelled oligonucleotides used as probes for DNA/RNA hybridization assays, genotyping, and diagnostics.Peptide and Oligonucleotide CDMO Market1 by End User: Pharmaceutical and Biotechnology Companies: These include large pharmaceutical companies and emerging biotech firms outsourcing their peptide and oligonucleotide manufacturing processes to CDMOs. Research Institutions: Academic and research institutions utilize CDMO services for synthesizing peptides and oligonucleotides for various research purposes. Contract Research Organizations (CROs): CROs collaborate with CDMOs to support their clients' drug discovery and development programs by providing peptide and oligon.

Peptide and Oligonucleotide CDMO Market Regional analysis:

The report provides a comprehensive analysis of the growth, trends, and opportunities in the Peptide and Oligonucleotide CDMO (Contract Development and Manufacturing Organization) market across different regions. The market is segmented by region, service type, and end-use industry. North America dominates the market, benefiting from major players, advanced research infrastructure, and a high demand for peptide and oligonucleotide CDMO services in the biotechnology and pharmaceutical industries. The region has well-established sectors that require contract manufacturing services for the development and production of peptides and oligonucleotides used in therapeutics, diagnostics, and research applications. Europe holds a significant share in the market, driven by its strong biotechnology and pharmaceutical industry and the presence of key market players. The region has a robust regulatory framework and high-quality standards, which contribute to the adoption of peptide and oligonucleotide CDMO services for the development and manufacturing of advanced therapeutics and diagnostic products. The Asia-Pacific region emerges as a rapidly growing market, fuelled by the expansion of the biotechnology and pharmaceutical industries, increasing investments in research and development, and growing demand for peptide and oligonucleotide-based products. Countries like China, India, and South Korea are witnessing significant growth in the adoption of CDMO services for peptide and oligonucleotide synthesis and manufacturing. Latin America and the Middle East and Africa experience moderate growth rates in the Peptide and Oligonucleotide CDMO market. These regions are gradually investing in healthcare infrastructure, fostering collaborations with global pharmaceutical companies, and increasing awareness about advanced biologics and diagnostic technologies, which drives the demand for contract development and manufacturing services. The global Peptide and Oligonucleotide CDMO market presents diverse growth prospects, driven by the expanding biotechnology and pharmaceutical industries, increasing demand for peptide and oligonucleotide-based therapeutics and diagnostics, and advancements in research and development activities across different regions.

Peptide and Oligonucleotide CDMO Market Competitive landscape:

The market report offers an in-depth analysis of the competitive landscape of the peptide and oligonucleotide contract development and manufacturing organization (CDMO) market, including the major players and their strategies. Some of the key companies in the market include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Ajinomoto Co., Inc., Wuxi Apptec Co., Ltd., and Rentschler Biopharma SE. The report examines the market based on factors such as capabilities in peptide and oligonucleotide synthesis, manufacturing capacity, regulatory compliance, quality control, and customer service. It provides insights into the competitive strategies of these companies, including investments in R&D, collaborations, partnerships, and acquisitions to expand their capabilities and market presence. The report highlights the key trends and challenges in the peptide and oligonucleotide CDMO market, such as the increasing demand for personalized medicine, advancements in peptide and oligonucleotide therapeutics, and the need for efficient and cost-effective manufacturing processes. The report provides an overview of the global peptide and oligonucleotide CDMO market, including its size, growth rate, and revenue forecast for the coming years. It also includes information on the market segmentation by service type (peptide synthesis, oligonucleotide synthesis, conjugation, purification, analytical services, and others), end-user (pharmaceutical and biotechnology companies, research institutions, and others), and geography. The competitive landscape of the peptide and oligonucleotide CDMO market is characterized by intense competition among the key players, with a focus on innovation, technological advancements, and strategic partnerships to gain a competitive edge. The market players are also expanding their geographical presence and investing in state-of-the-art facilities to meet the increasing demand for peptide and oligonucleotide therapeutics.

Peptide and Oligonucleotide CDMO Market Scope: Inquire before buying

Peptide and Oligonucleotide CDMO Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2017 to 2022 Market Size in 2022: US $ 1.7 Bn.
Forecast Period 2023 to 2029 CAGR: 10.7% Market Size in 2029: US $ 3.4 Bn.
Segments Covered: by Product 1.Peptide CDMO 2.Oligonucleotide CDMO
by Application 1. Therapeutics 2.Research Applications 3.Diagnostics 4. Other Applications
by End Users 1.Pharmaceutical and Biotechnology Companies 2.Research Institutes 3.Contract Research Organizations (CROs) 4.Academic and Government Organizations

Peptide and Oligonucleotide CDMO Market, by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Peptide and Oligonucleotide CDMO Market Key Players:

The report has in detail information about the strategies adopted by the following key players to sustain and grow in the market. These Peptide and Oligonucleotide CDMO players covered in the report are selected on the basis of certain criteria. 1. Lonza Group Ltd. (Europe, North America, Asia-Pacific) 2. Thermo Fisher Scientific Inc. (North America, Europe, Asia-Pacific) 3.Merck KGaA (Europe, North America, Asia-Pacific) 4. Catalent, Inc. (North America, Europe, Asia-Pacific) 5. Genscript Biotech Corporation (North America, Europe, Asia-Pacific) 6. Polypeptide Group (Europe, North America, Asia-Pacific) 7. Bachem Holding AG (Europe, North America, Asia-Pacific) 8. Ajinomoto Co., Inc. (Asia-Pacific, Europe, North America) 9. Wuxi Apptec Co., Ltd. (Asia-Pacific, Europe, North America) 10. Rentschler Biopharma SE (Europe, North America) 11. CordenPharma International (Europe, North America, Asia-Pacific) 12.Senn Chemicals AG (Europe, North America, Asia-Pacific) 13. PolyPeptide Group (Europe, North America, Asia-Pacific) 14.Almac Group (Europe, North America, Asia-Pacific) 15.Lonza Custom Manufacturing (Europe, North America, Asia-Pacific) 16.AMRI Global (North America, Europe, Asia-Pacific) 17. Creative Peptides (North America, Europe, Asia-Pacific) 18.Swiss Customized Synthesis (Europe, North America, Asia-Pacific) 19. BACHEM AMERICA (North America, Europe, Asia-Pacific) 20.CPC Scientific Inc. (North America, Europe, Asia-Pacific) 21. Syngene (Asia-Pacific, Europe, North America) 22. ProSpec-Tany TechnoGene Ltd. (Europe, North America, Asia-Pacific) 23. AnaSpec (Europe, North America, Asia-Pacific) 24. Eurogentec (Europe, North America, Asia-Pacific) 25.CPC Scientific Inc. (North America, Europe, Asia-Pacific) Frequently Asked Questions: 1] What segments are covered in the Peptide and Oligonucleotide CDMO Market report? Ans. The segments covered in the Peptide and Oligonucleotide CDMO Market report are based on product type, type, application, end-user, and geography. 2] Which region is expected to hold the highest share in Peptide and Oligonucleotide CDMO Market? Ans. The North America region is expected to hold the highest share in Peptide and Oligonucleotide CDMO Market. 3] What is the market size of the Peptide and Oligonucleotide CDMO market by 2029? Ans. The market size of the Peptide and Oligonucleotide CDMO Market by 2029 is expected to reach US $ 3.4 billion. 4] What is the forecast period for the Peptide and Oligonucleotide CDMO Market? Ans. The Forecast period for the Peptide and Oligonucleotide CDMO Market is 2023-2029. 5] What was the market size of the Peptide and Oligonucleotide CDMO Market in 2022? Ans. The market size of Peptide and Oligonucleotide CDMO Market in 2022 was US $ 1.7 billion.
1. Peptide and Oligonucleotide CDMO Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Peptide and Oligonucleotide CDMO Market: Dynamics 2.1. Peptide and Oligonucleotide CDMO Market Trends by Region 2.1.1. North America Peptide and Oligonucleotide CDMO Market Trends 2.1.2. Europe Peptide and Oligonucleotide CDMO Market Trends 2.1.3. Asia Pacific Peptide and Oligonucleotide CDMO Market Trends 2.1.4. Middle East and Africa Peptide and Oligonucleotide CDMO Market Trends 2.1.5. South America Peptide and Oligonucleotide CDMO Market Trends 2.2. Peptide and Oligonucleotide CDMO Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Peptide and Oligonucleotide CDMO Market Drivers 2.2.1.2. North America Peptide and Oligonucleotide CDMO Market Restraints 2.2.1.3. North America Peptide and Oligonucleotide CDMO Market Opportunities 2.2.1.4. North America Peptide and Oligonucleotide CDMO Market Challenges 2.2.2. Europe 2.2.2.1. Europe Peptide and Oligonucleotide CDMO Market Drivers 2.2.2.2. Europe Peptide and Oligonucleotide CDMO Market Restraints 2.2.2.3. Europe Peptide and Oligonucleotide CDMO Market Opportunities 2.2.2.4. Europe Peptide and Oligonucleotide CDMO Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Peptide and Oligonucleotide CDMO Market Drivers 2.2.3.2. Asia Pacific Peptide and Oligonucleotide CDMO Market Restraints 2.2.3.3. Asia Pacific Peptide and Oligonucleotide CDMO Market Opportunities 2.2.3.4. Asia Pacific Peptide and Oligonucleotide CDMO Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Peptide and Oligonucleotide CDMO Market Drivers 2.2.4.2. Middle East and Africa Peptide and Oligonucleotide CDMO Market Restraints 2.2.4.3. Middle East and Africa Peptide and Oligonucleotide CDMO Market Opportunities 2.2.4.4. Middle East and Africa Peptide and Oligonucleotide CDMO Market Challenges 2.2.5. South America 2.2.5.1. South America Peptide and Oligonucleotide CDMO Market Drivers 2.2.5.2. South America Peptide and Oligonucleotide CDMO Market Restraints 2.2.5.3. South America Peptide and Oligonucleotide CDMO Market Opportunities 2.2.5.4. South America Peptide and Oligonucleotide CDMO Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Peptide and Oligonucleotide CDMO Industry 2.8. Analysis of Government Schemes and Initiatives For Peptide and Oligonucleotide CDMO Industry 2.9. Peptide and Oligonucleotide CDMO Market Trade Analysis 2.10. The Global Pandemic Impact on Peptide and Oligonucleotide CDMO Market 3. Peptide and Oligonucleotide CDMO Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 3.1.1. Peptide CDMO 3.1.2. Oligonucleotide CDMO 3.2. Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 3.2.1. Therapeutics 3.2.2. Research Applications 3.2.3. Diagnostics 3.2.4. Other Applications 3.3. Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 3.3.1. Pharmaceutical and Biotechnology Companies 3.3.2. Research Institutes 3.3.3. Contract Research Organizations (CROs) 3.3.4. Academic and Government Organizations 3.4. Peptide and Oligonucleotide CDMO Market Size and Forecast, by Region (2022-2029) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Peptide and Oligonucleotide CDMO Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 4.1.1. Peptide CDMO 4.1.2. Oligonucleotide CDMO 4.2. North America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 4.2.1. Therapeutics 4.2.2. Research Applications 4.2.3. Diagnostics 4.2.4. Other Applications 4.3. North America Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 4.3.1. Pharmaceutical and Biotechnology Companies 4.3.2. Research Institutes 4.3.3. Contract Research Organizations (CROs) 4.3.4. Academic and Government Organizations 4.4. North America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Country (2022-2029) 4.4.1. United States 4.4.1.1. United States Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 4.4.1.1.1. Peptide CDMO 4.4.1.1.2. Oligonucleotide CDMO 4.4.1.2. United States Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 4.4.1.2.1. Therapeutics 4.4.1.2.2. Research Applications 4.4.1.2.3. Diagnostics 4.4.1.2.4. Other Applications 4.4.1.3. United States Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 4.4.1.3.1. Pharmaceutical and Biotechnology Companies 4.4.1.3.2. Research Institutes 4.4.1.3.3. Contract Research Organizations (CROs) 4.4.1.3.4. Academic and Government Organizations 4.4.2. Canada 4.4.2.1. Canada Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 4.4.2.1.1. Peptide CDMO 4.4.2.1.2. Oligonucleotide CDMO 4.4.2.2. Canada Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 4.4.2.2.1. Therapeutics 4.4.2.2.2. Research Applications 4.4.2.2.3. Diagnostics 4.4.2.2.4. Other Applications 4.4.2.3. Canada Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 4.4.2.3.1. Pharmaceutical and Biotechnology Companies 4.4.2.3.2. Research Institutes 4.4.2.3.3. Contract Research Organizations (CROs) 4.4.2.3.4. Academic and Government Organizations 4.4.3. Mexico 4.4.3.1. Mexico Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 4.4.3.1.1. Peptide CDMO 4.4.3.1.2. Oligonucleotide CDMO 4.4.3.2. Mexico Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 4.4.3.2.1. Therapeutics 4.4.3.2.2. Research Applications 4.4.3.2.3. Diagnostics 4.4.3.2.4. Other Applications 4.4.3.3. Mexico Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 4.4.3.3.1. Pharmaceutical and Biotechnology Companies 4.4.3.3.2. Research Institutes 4.4.3.3.3. Contract Research Organizations (CROs) 4.4.3.3.4. Academic and Government Organizations 5. Europe Peptide and Oligonucleotide CDMO Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.2. Europe Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.3. Europe Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 5.4. Europe Peptide and Oligonucleotide CDMO Market Size and Forecast, by Country (2022-2029) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.1.2. United Kingdom Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.1.3. United Kingdom Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users(2022-2029) 5.4.2. France 5.4.2.1. France Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.2.2. France Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.2.3. France Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users(2022-2029) 5.4.3. Germany 5.4.3.1. Germany Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.3.2. Germany Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.3.3. Germany Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 5.4.4. Italy 5.4.4.1. Italy Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.4.2. Italy Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.4.3. Italy Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users(2022-2029) 5.4.5. Spain 5.4.5.1. Spain Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.5.2. Spain Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.5.3. Spain Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 5.4.6. Sweden 5.4.6.1. Sweden Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.6.2. Sweden Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.6.3. Sweden Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 5.4.7. Austria 5.4.7.1. Austria Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.7.2. Austria Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.7.3. Austria Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 5.4.8.2. Rest of Europe Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 5.4.8.3. Rest of Europe Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6. Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.2. Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.3. Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4. Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast, by Country (2022-2029) 6.4.1. China 6.4.1.1. China Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.1.2. China Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.1.3. China Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.2. S Korea 6.4.2.1. S Korea Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.2.2. S Korea Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.2.3. S Korea Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.3. Japan 6.4.3.1. Japan Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.3.2. Japan Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.3.3. Japan Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.4. India 6.4.4.1. India Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.4.2. India Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.4.3. India Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.5. Australia 6.4.5.1. Australia Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.5.2. Australia Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.5.3. Australia Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.6. Indonesia 6.4.6.1. Indonesia Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.6.2. Indonesia Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.6.3. Indonesia Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.7. Malaysia 6.4.7.1. Malaysia Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.7.2. Malaysia Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.7.3. Malaysia Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.8. Vietnam 6.4.8.1. Vietnam Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.8.2. Vietnam Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.8.3. Vietnam Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users(2022-2029) 6.4.9. Taiwan 6.4.9.1. Taiwan Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.9.2. Taiwan Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.9.3. Taiwan Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 6.4.10.2. Rest of Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 6.4.10.3. Rest of Asia Pacific Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 7. Middle East and Africa Peptide and Oligonucleotide CDMO Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 7.2. Middle East and Africa Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 7.3. Middle East and Africa Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 7.4. Middle East and Africa Peptide and Oligonucleotide CDMO Market Size and Forecast, by Country (2022-2029) 7.4.1. South Africa 7.4.1.1. South Africa Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 7.4.1.2. South Africa Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 7.4.1.3. South Africa Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 7.4.2. GCC 7.4.2.1. GCC Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 7.4.2.2. GCC Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 7.4.2.3. GCC Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 7.4.3. Nigeria 7.4.3.1. Nigeria Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 7.4.3.2. Nigeria Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 7.4.3.3. Nigeria Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 7.4.4.2. Rest of ME&A Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 7.4.4.3. Rest of ME&A Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 8. South America Peptide and Oligonucleotide CDMO Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 8.2. South America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 8.3. South America Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users(2022-2029) 8.4. South America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Country (2022-2029) 8.4.1. Brazil 8.4.1.1. Brazil Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 8.4.1.2. Brazil Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 8.4.1.3. Brazil Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 8.4.2. Argentina 8.4.2.1. Argentina Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 8.4.2.2. Argentina Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 8.4.2.3. Argentina Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Product (2022-2029) 8.4.3.2. Rest Of South America Peptide and Oligonucleotide CDMO Market Size and Forecast, by Application (2022-2029) 8.4.3.3. Rest Of South America Peptide and Oligonucleotide CDMO Market Size and Forecast, by End Users (2022-2029) 9. Global Peptide and Oligonucleotide CDMO Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Peptide and Oligonucleotide CDMO Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Lonza Group Ltd. (Europe, North America, Asia-Pacific) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Thermo Fisher Scientific Inc. (North America, Europe, Asia-Pacific) 10.3. Merck KGaA (Europe, North America, Asia-Pacific) 10.4. Catalent, Inc. (North America, Europe, Asia-Pacific) 10.5. Genscript Biotech Corporation (North America, Europe, Asia-Pacific) 10.6. Polypeptide Group (Europe, North America, Asia-Pacific) 10.7. Bachem Holding AG (Europe, North America, Asia-Pacific) 10.8. Ajinomoto Co., Inc. (Asia-Pacific, Europe, North America) 10.9. Wuxi Apptec Co., Ltd. (Asia-Pacific, Europe, North America) 10.10. Rentschler Biopharma SE (Europe, North America) 10.11. CordenPharma International (Europe, North America, Asia-Pacific) 10.12. Senn Chemicals AG (Europe, North America, Asia-Pacific) 10.13. PolyPeptide Group (Europe, North America, Asia-Pacific) 10.14. Almac Group (Europe, North America, Asia-Pacific) 10.15. Lonza Custom Manufacturing (Europe, North America, Asia-Pacific) 10.16. AMRI Global (North America, Europe, Asia-Pacific) 10.17. Creative Peptides (North America, Europe, Asia-Pacific) 10.18. Swiss Customized Synthesis (Europe, North America, Asia-Pacific) 10.19. BACHEM AMERICA (North America, Europe, Asia-Pacific) 10.20. CPC Scientific Inc. (North America, Europe, Asia-Pacific) 10.21. Syngene (Asia-Pacific, Europe, North America) 10.22. ProSpec-Tany TechnoGene Ltd. (Europe, North America, Asia-Pacific) 10.23. AnaSpec (Europe, North America, Asia-Pacific) 10.24. Eurogentec (Europe, North America, Asia-Pacific) 10.25. CPC Scientific Inc. (North America, Europe, Asia-Pacific) 11. Key Findings 12. Industry Recommendations 13. Peptide and Oligonucleotide CDMO Market: Research Methodology 14. Terms and Glossary
  • INQUIRE BEFORE BUYING